Cancer Genetics and Tumor Progression
Xeroderma pigmentosum (XP): An inherited disorder caused by mutations in nucleotide excision repair (NER) genes (e.g., XPA-G). This impairs DNA damage repair, leading to extreme UV sensitivity, high risk of skin cancers (basal cell carcinoma, squamous cell carcinoma, melanoma), and neurological issues. Highlights DNA repair's crucial role in cancer suppression.
Cancer Cell Characteristics:
Normal cells: Exhibit limited divisions (replicative senescence) due to telomere shortening.
Cancer cells: Are immortal, bypassing senescence and dividing indefinitely, often by reactivating telomerase to maintain telomere length.
Processes Contributing to Cancer:
Angiogenesis: Formation of new blood vessels from pre-existing ones, induced by tumors (e.g., via VEGF) to supply oxygen and nutrients, supporting rapid growth.
Metastasis: Cancer spread from a primary tumor to distant sites via blood or lymphatic vessels, forming secondary tumors. This complex process (local invasion, intravasation, extravasation, colonization) is the main cause of cancer mortality and complicates treatment.
Tumor Development:
Occurs through clonal evolution, where multiple somatic gene mutations accumulate sequentially within a single cell lineage. Each mutation confers a selective advantage, driving tumor progression and leading to increasingly aggressive phenotypes.
Pre-cancerous Lesions:
Abnormal cell growths with the potential to become invasive cancers.
Examples:
Adenomas: Benign glandular tumors (e.g., colon polyps) that can progress to adenocarcinoma.
Fibromas: Benign tumors of fibrous tissue.
Dysplasia: Abnormal cell growth (size, shape, organization) often monitored or removed (e.g., cervical dysplasia, prostate intraepithelial neoplasia ) to prevent malignant transformation.
Colorectal Cancer Progression:
Follows an adenoma-carcinoma sequence, where specific gene mutations are linked to pathological stages.
Key mutations:
APC: Initial mutation, leading to epithelial hyperproliferation.
KRAS: Promotes growth and inhibits apoptosis.
TP53: Contributes to genetic instability and progression to invasive carcinoma.
Endoscopy (e.g., colonoscopy) is crucial for early detection and removal of polyps.
Melanoma Genomics:
Exhibits diverse mutation landscapes based on subtype and etiology.
Cutaneous melanoma: Strongly linked to UV exposure, characterized by transition mutations.
Key driver mutations include:
BRAF (): Found in ~ of melanomas, activating the MAP kinase pathway.
NRAS: Found in ~ of melanomas, also activating the MAP kinase pathway.
TP53: Tumor suppressor gene, contributing to genomic instability.
Other subtypes (e.g., acral, mucosal) have different profiles (e.g., KIT mutations).
Driver vs. Passenger Mutations:
Driver mutations: Directly contribute to cancer development by conferring a selective growth advantage; positively selected during tumor evolution. Critical targets for therapy.
Passenger mutations: Neutral mutations that accumulate without contributing to cancer development.
Epigenetic Factors:
Changes like DNA methylation and involvement of microRNAs significantly influence gene expression and cancer progression without altering the underlying DNA sequence.
Steps to Malignancy:
Intracellular signaling enhances proliferation.
Growth-inhibiting signals become ineffective.
Evade programmed cell death.
Limitless replicative potential.
Development of independent nutrient sources.
Ability to invade and colonize new tissues.